Phibro Animal Health Corporation revised earnings guidance for the fiscal year ending June 30, 2023. For the year, the company expects net sales of $960 million - $1 billion (unchanged); net income of $34 million- $38 million, from $39 million- $43 million; diluted EPS of $0.84 - $0.94, from $0.96 - $1.06.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.78 USD | +31.81% | +28.58% | +44.91% |
Apr. 29 | Zoetis to Sell Medicated-Feed-Additive Portfolio to Phibro for $350 Million | DJ |
Apr. 29 | Zoetis to Sell Medicated Feed Additives Business to Phibro Animal Health for $350 Million | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+44.91% | 680M | |
-19.09% | 72.97B | |
-8.93% | 6.69B | |
+21.38% | 3.6B | |
+1.52% | 1.44B | |
-16.99% | 1.34B | |
-7.13% | 1.25B | |
-26.05% | 1.24B | |
-12.71% | 1.15B | |
-4.03% | 1.01B |
- Stock Market
- Equities
- PAHC Stock
- News Phibro Animal Health Corporation
- Phibro Animal Health Corporation Revises Earnings Guidance for the Fiscal Year Ending June 30, 2023